Furthermore, Barbie et al27 found that treatment of IKBKE‐driven breast cancer cells with CYT387, a potent inhibitor of TBK1/IKBKE and JAK signaling, reduced the proliferation and migration of TNBC cells, whereas inhibition of JAK alone does not. Here, IKBKE is linked to breast carcinoma.